FDA Explores Faster Track for Early Drug Testing
Published Date: 6/24/2026
Notice
Summary
The FDA wants to speed up how fast new drugs get tested on people by creating a special pilot program. This program will team up trusted research groups with drug makers to review early study plans faster, while keeping safety top priority. If you’re involved in drug research or healthcare, now’s your chance to share ideas before July 22, 2026!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Faster First‑in‑Human Trials
FDA proposes a pilot to shorten the time from nonclinical research to first‑in‑human (FIH) studies by using qualified research institutions (QRIs), a rolling IND submission platform, and parallel activities like IRB review and site contracting. The pilot would allow FDA to review IND components on a rolling basis and could result in a "safe to proceed" notification before the 30‑day IND review period ends and fewer Phase 1 clinical holds.
Sponsors Pay QRIs Directly
The notice states that following the pilot, FDA expects sponsors will pay fees directly to Qualified Research Institutions (QRIs), and FDA will not set or collect those fees. Sponsors that participate should expect to pay QRIs for services after the pilot.
FDA Keeps Final Decision Authority
FDA will limit QRIs to advisory roles and will remain solely responsible for regulatory decisions. FDA retains authority to issue clinical holds, disqualify investigators, disqualify or restrict IRBs or institutions, require safety reporting, and conduct inspections.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-12620, Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availability
The FDA just dropped a fresh draft guidance to help drug and biological product makers run smarter, faster clinical trials using master protocols. This update affects companies developing new medicines by clarifying how to design and submit these trials for approval. If you’re in the game, get your comments in by August 24, 2026, or risk missing out on shaping the final rules—and maybe saving time and money down the road!
Next: 2026-12622, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availability
The FDA just released a new draft guide to help drug makers prove their medicines really work, using smarter and faster science. This update affects companies developing human drugs and biological products, aiming to save time and money by allowing strong evidence from just one good clinical study plus extra proof. Comments on this draft are open until September 22, 2026, so industry folks have a chance to weigh in before it becomes final.